Jideytro Becomes GSK’s First Lung-Cancer Medicine

Company GSK / Nuvalent Event Type Regulatory Approval (FDA) Modality Small-Molecule Kinase Inhibitor Asset Jideytro (Zidesamtinib) Target ROS1 Kinase Disease Area ROS1-Positive Non-Small Cell Lung Cancer Summary The FDA approved Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer previously…